Intercept Pharma (ICPT) Receives a Buy from Oppenheimer

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Intercept Pharma (ICPTResearch Report), with a price target of $146.00. The company’s shares closed last Monday at $112.86.

According to TipRanks.com, Olson ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.1% and a 36.1% success rate. Olson covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, CymaBay Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on Intercept Pharma is a Strong Buy with an average price target of $163.38, a 45.4% upside from current levels. In a report issued on January 3, Wedbush also maintained a Buy rating on the stock with a $257.00 price target.

See today’s analyst top recommended stocks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $84.83 million. In comparison, last year the company had a GAAP net loss of $88.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.